you are an idiot. This went straight up from $2.75 to $9.00 in 8 weeks and now it pulls back a little and you are upset. It will rise again but it has to take a breather. Nothing goes straight up. Sounds like you came late to the party. Go to another board, we don't want you.
this will never reach $100 they themselves just cut their earning a lot by making a deal with ESRX. Cutting the price means cutting the profits. It is as simple as that.
but the ABBV price is $83,000 except to ESRX which isn't much cheaper. Don't you think all the others will want the lower price too and ABBV won't make any money. LOL
because they are not going to make as much on their drug as they thought because they had to make this deal with ESRX to get their drugs prescribed.
You would never ramp up production enough before it was approved, enough to supply every pharmacy in the country. Do you know how many pills that is? This company could not afford the risk.
Sovaldi, which was approved late last year, costs $84,000 for a course of treatment. AbbVie has said the shortest approved course of therapy for Viekira, 12 weeks, will cost about $83,320 at wholesale prices. The only reason esrx is going with them is for the discount. Now that there is competition Gild will discount their drug also. ABBV's price normally is only a few $100's cheaper and you have to take 6 pills a day instead of 1. I don't think many doctors are going to switch.
Are they going to have this ready for launch Jan. 1? It will be pretty bad if they cut Gild out Jan 1 and their patients can't even get ABBV's drug because they don't have enough in production by then. Or worse start people's regimen and then don't have pills for the refills.
I lost my #$%$ on DNDN and it got approval but the doctors love the current chemo. It makes them a lot of money, So they will probably not use this drug either. It will put them out of business along with all the cancer hospitals.
CNBC sure likes BABA. They have shown that interview with Ma about 10 times. When they get on 1 stock they never let it rest. look how they handled Apple, they beat it up all the way down to $398. Now they love it at $ 780 pre 7/1 split. I think they get paid to promote stocks or run stocks in the ground.
this is a cure, but I was wondering, can these same individuals get Hep C again? And if so will the insurance companies pay for a second treatment.
this side effect is a good thing in dialysis patients. In addition to decreasing Phosphate levels it increases iron which dialysis patients are low on iron anyway. It is like Benadryl causes drowsiness. So J&J puts Benadryl in with Tylenol to make Tylenol PM to cause you to fall asleep at night. So to me instead of saying drowsiness is a side effect in Tylenol PM it is the action they want to achieve. So they should market Kerx's drug as having 2 benefits, lowering phosphates while elevating Iron. I think the FDA should have also made them change the name a long time ago. Now if they have already been talking to doctors about Zerenex they will now think this is a different entity
it they sell their drug to poor countries for $900 vs $84,000 in the US, sounds like you are setting up a black market for this drug. So the theifs will make all the money and not the stockholders.